Cover Image
市場調查報告書

癌症免疫療法市場·臨床實驗平台分析

Cancer Immunotherapy Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 308563
出版日期 內容資訊 英文 1990 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法市場·臨床實驗平台分析 Cancer Immunotherapy Market & Clinical Pipeline Insight
出版日期: 2014年07月22日 內容資訊: 英文 1990 Pages
簡介

2013年全球有600萬以上的人因為癌症而死,癌症幾乎是全球所有經濟各國面臨的緊急醫療問題之一。癌症免疫療法是在癌症治療領域上一大具有莫大可能性的治療法之一。

本報告提供全球癌症免疫療法市場與新藥的開發趨勢相關調查,提供您癌症免疫療法市場概要,癌症免疫療法市場力學,癌症免疫療法的開發平台,以及依Phase·國別提供癌症單株抗體,癌症疫苗,腫瘤溶解性病毒,癌症細胞因子治療,及癌症細胞療法臨床實驗分析,再彙整主要醫藥品經營者簡介等。

第1章 簡介:癌症免疫療法

第2章 癌症免疫療法的機制

  • 基因工程學
  • 融合瘤細胞技術
  • 單株抗體的人型化
  • 克服現代技術的HAMA反應

第3章 癌症免疫療法的種類

  • 單株抗體
  • 檢查站抑制劑
  • 疫苗接種
  • 非特異性免疫療法

第4章 需要癌症免疫療法的理由

第5章 全球癌症免疫療法市場概要

第6章 癌症免疫療法市場動態

  • 有利的市場成長促進要素
  • 議論的主要課題
  • 癌症免疫療法的未來

第7章 癌症單株抗體的臨床實驗平台:Phase、國別

  • 臨床開發平台概要
  • 臨床實驗平台分析:從研究到登記
  • 市售的癌症單株抗體

第8章 癌症疫苗的臨床實驗平台:Phase、國別

  • 臨床開發平台概要
  • 臨床實驗平台分析:從研究到登記
  • 市售的癌症疫苗

第9章 腫瘤溶解性病毒的臨床實驗平台:Phase、國別

  • 臨床開發平台概要
  • 臨床實驗平台分析:從研究到登記

第10章 癌症細胞因子治療臨床實驗分析:Phase、國別

  • 臨床開發平台概要
  • 臨床實驗平台分析:從研究到登記
  • 市售的癌症細胞因子治療藥

第11章 癌症細胞療法臨床實驗分析:Phase、國別

  • 臨床開發平台概要
  • 臨床實驗平台分析:從研究到登記
  • 市售的癌症細胞治療藥

第12章 競爭情形:產業概要·產品平台

  • Advaxis
  • Celldex Therapeutics
  • Dendreon Corporation
  • Galena Biopharma
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Roche
  • Seattle Genetics

圖表

目錄

With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body's immune system in order to target the cancer.

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system.

There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.

Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.

“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:

  • Cancer Immunotherapy Market Overview
  • Cancer Immunotherapy Market Dynamics
  • Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
  • Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
  • Cancer Vaccine Clinical Pipeline by Phase & Country
  • Oncolytic Viruses Clinical Pipeline by Phase & Country
  • Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
  • Cancer Cell Therapy Clinical Trial Insight by Phase & Country
  • Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

Table of Contents

1. Introduction to Cancer Immunotherapy

2. Mechanism of Cancer Immunotherapy

  • 2.1. Genetic engineering
  • 2.2. Hybridoma Technology
  • 2.3. Humanization of Monoclonal Antibodies
  • 2.4. Overcoming the HAMA Response via Modern Technology

3. Types of Cancer Immunotherapy

  • 3.1. Monoclonal Antibodies
  • 3.2. Checkpoint Inhibitors
  • 3.3. Vaccination
  • 3.4. Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy

5. Global Cancer Immunotherapy Market Overview

6. Cancer Immunotherapy Market Dynamics

  • 6.1. Favorable Market Drivers
  • 6.2. Key issues to be Discussed
  • 6.3. Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country

  • 7.1. Clinical Pipeline Overview
  • 7.2. Clinical Pipeline Insight: Research till Registration
  • 7.3. Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country

  • 8.1. Clinical Pipeline Overview
  • 8.2. Clinical Pipeline Insight: Research till Registration
  • 8.3. Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country

  • 9.1. Clinical Pipeline Overview
  • 9.2. Clinical Pipeline insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country

  • 10.1. Clinical Pipeline Overview
  • 10.2. Clinical Pipeline Insight: Research till Preregistration
  • 10.3. Marketed Cancer Cytokines Threapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country

  • 11.1. Clinical Pipeline Overview
  • 11.2. Clinical Pipeline Insight: Research till Preregistration
  • 11.3. Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline

  • 12.1. Advaxis
  • 12.2. Celldex Therapeutics
  • 12.3. Dendreon Corporation
  • 12.4. Galena Biopharma
  • 12.5. ImmunoCellular Therapeutics
  • 12.6. ImmunoGen
  • 12.7. Inovio Pharmaceuticals
  • 12.8. Merck
  • 12.9. NeoStem Oncology
  • 12.10. NewLink Genetics
  • 12.11. Northwest Biotherapeutics
  • 12.12. Novartis
  • 12.13. Peregrine Pharmaceuticals
  • 12.14. Roche
  • 12.15. Seattle Genetics

List of Figures

  • Figure 1-1: Introduction to Cancer Therapies
  • Figure 1-2: Key Events in the History of Cancer Immunotherapy
  • Figure 2-1: Mechanism of Cancer Immunotherapy
  • Figure 3-1: Type of Cancer Immunotherapy
  • Figure 5-1: Cancer Immunotherapy Market Category
  • Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
  • Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
  • Figure 5-4: Regulatory Milestones for Cancer Immunotherapy
  • Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
  • Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014
  • Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
  • Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014
  • Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
  • Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014
  • Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 12-1: Advaxis Clinical Pipeline
  • Figure 12-2: Celldex Therapeutics Clinical Pipeline
  • Figure 12-3: Galena Biopharma Clinical Pipeline
  • Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 12-5: ImmunoGen Clinical Pipeline
  • Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
  • Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
  • Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 12-10: Seattle Genetics Clinical Pipeline
Back to Top